A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer

TTP Clinical Trial

Official title:

A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer Treated With Pyrrolidine Maleate and Capecitabine Combined With Brain Radiotherapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04767828
• Other study ID #: E2019316
• Status: Recruiting
• Phase: Phase 4
• Start date: May 1, 2020
• Est. completion date: June 2022

Study information

• Verified date: February 2021
• Source: Tianjin Medical University Cancer Institute and Hospital
• Contact: Jing Wang, MD
• Phone: 13920762182
• Email: wj62182[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study was to evaluate the progression time and efficacy of brain tumors in patients with brain metastases from HER2-positive breast cancer treated with Pyrrolidine and Capecitabine combined with brain radiotherapy.

Description:

Brain metastases are very common in HER2-positive breast cancer patients. The vast majority of patients with metastatic brain tumors are in advanced stages of the disease. If not treated in time, the natural course of the disease is extremely short. At present, the main treatment of brain metastases from breast cancer is radiotherapy, combined with chemotherapy and targeted therapy drugs. On the basis of previous clinical studies, the aim of this study was to explore the efficacy and safety of combined brachytherapy with Pyrrotidine and Capecitabine in patients with brain metastases from HER2-positive breast cancer, in order to provide a new, safer and more effective treatment for patients with brain metastases from breast cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 43
• Est. completion date: June 2022
• Est. primary completion date: June 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Signed written informed consent prior to enrollment.

2. Age 18-75 years, female.

3. Patients with pathologically confirmed HER2 expression-positive breast cancer brain metastases; HER2 expression-positive refers to those with a standard immunohistochemical staining (IHC) test showing HER2 as 3+ and/or fluorescence in situ hybridization technique (FISH) positive (confirmed by investigator review at their trial center).

4. The presence of CNS lesions as confirmed by cranial CT or MRI.

5. ECOG score: 0 to 2.

6. Expected survival of not less than 12 weeks.

7. having received no previous brain radiotherapy or having received brain radiotherapy at the dose specified in the trial protocol.

8. Patients who have been on pyrrolizidine for = 3 months after diagnosis of brain metastases and whose disease has not progressed.

9. The function of vital organs meets the following requirements (excluding the use of any blood components and cell growth factors within 14 days).

A) Routine blood examination criteria need to be met: Hb = 100 g/L; ANC = 1.5×109 /L; PLT = 75×109 /L B) Biochemical examination should meet the following criteria: TBIL=1.5×ULN (upper limit of normal); ALT and AST=2.5×ULN; ALT and AST=5×ULN if liver metastasis; serum creatinine=1.5×ULN, creatinine clearance=50ml/min (based on Cockroft and Gault formula) C) Cardiac ultrasound; left ventricular ejection fraction (LVEF) = 50%

10. Female patients who are non-surgically sterilized or of childbearing age are required to use a medically approved form of contraception (e.g., IUD, pill, or condom) during and for 3 months after the end of the study treatment period; female patients of childbearing age who are non-surgically sterilized must have a negative serum or urine HCG test within 7 days prior to study enrollment; and must be non-lactating.

11. Subjects are voluntarily enrolled in the study, are compliant, and cooperate with safety and survival follow-up.

Exclusion Criteria:

1. Presence of third interstitial fluid that cannot be controlled by drainage or other methods, such as massive pleural and ascites fluid.

2. the presence of multiple factors that interfere with oral administration and absorption of the drug (e.g., inability to swallow, post-gastrectomy, chronic diarrhea, and intestinal obstruction).

3. have a proven allergy to the drug components of this regimen.

4. Patients who are known to be pregnant or planning to become pregnant, or patients of gestational age who are unwilling to use effective contraception throughout the trial period.

5. Patients with severe concomitant disease or who, in the opinion of the investigator, are not suitable for inclusion.

6. Patients with the presence of meningeal metastases.

7. having participated in a clinical trial of another drug within 4 weeks prior to enrollment.

8. Patients who have used capecitabine during the neoadjuvant/adjuvant phase of therapy are allowed to be enrolled, but those who are ineffective or cannot tolerate capecitabine during the neoadjuvant/adjuvant phase of therapy need to be excluded; patients who have used capecitabine for = 3 months after brain metastasis and whose disease has not progressed can be enrolled; other drugs for which the active ingredient is 5-fluorouracil are treated as capecitabine (Note: " used capecitabine" refers to continuous standardized use of capecitabine for = 2 cycles).

9. Concurrently receiving other antitumor therapy.

Related Conditions & MeSH terms

• Neoplasm Metastasis
• TTP

Intervention

Drug:
• PYRROTINI
CAPECITABINE: 800 mg/m2 twice daily, taken orally within 30 minutes after meal (one in the morning and one in the evening, 12 hours apart, equal to a daily dose of 1600 mg/m2, with one dose in the morning and one dose in the morning) .

Radiation:
• Brain radiation therapy
Brain radiation therapy: the dose and frequency of brain radiation therapy are determined by the doctor according to the patient's condition.

Locations

Country	Name	City	State
China	Tianjin Medical University Cancer Institute and Hospital	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
Tianjin Medical University Cancer Institute and Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time of intracranial tumor progression	Objective to evaluate the intracranial tumor progression time of piratinib and capecitabine combined with brain radiotherapy for HER2 positive breast cancer patients with brain metastasis	through study completion, an average of 1 year
Secondary	Progression-free survival	Objective to evaluate the progression free survival (PFS) of pirotinib and capecitabine combined with brain radiotherapy in HER2 positive breast cancer patients with brain metastasis.	through study completion, an average of 1 year
Secondary	Objective remission rate	objective response rate (ORR) of pirotinib and capecitabine combined with brain radiotherapy in HER2 positive breast cancer patients with brain metastasis.	through study completion, an average of 1 year
Secondary	Duration of treatment effect	Duration of treatment effect (DCR) of pirotinib and capecitabine It refers to the time between the first assessment of CR or PR and the first assessment of PD (Progressive Disease) or death from any causecombined with brain radiotherapy in HER2 positive breast cancer patients with brain metastasis.	throughout studythrough study completion, an average of 1 year
Secondary	Disease control rate	Objective to evaluate the disease control rate of pirotinib and capecitabine combined with brain radiotherapy in HER2 positive breast cancer patients with brain metastasis	throughout studythrough study completion, an average of 1 year
Secondary	Clinical Benefit Rate	Objective to evaluate the clinical benefit rate of pirotinib and capecitabine combined with brain radiotherapy in HER2 positive breast cancer patients with brain metastasis	throughout studythrough study completion, an average of 1 year
Secondary	Overall survival	Objective to evaluate the overall survival of piratinib and capecitabine combined with brain radiotherapy in HER2 positive breast cancer patients with brain metastasis	through study completion, an average of 1 year
Secondary	Graded healing assessment	Objective to evaluate the effect of pyrrolotinib and capecitabine combined with brain radiotherapy in patients with HER2 positive breast cancer with brain metastasis,The score of graded healing assessment was 0-4. The higher the score, the better the result	through study completion, an average of 1 year